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Background: The widespread use of highly effective, combination antiretroviral therapy (cART) has led to a significant
reduction in the incidence of HIV-associated dementia (HAD). Despite these advances, the prevalence of HIV-1
associated neurocognitive disorders (HANDs) has been estimated at approximately 40%-50%. In the cART era, the
majority of this disease burden is represented by asymptomatic neurocognitive impairment and mild neurocognitive
disorder (ANI and MND respectively). Although less severe than HAD, these diagnoses carry with them substantial
morbidity.
Results: In this cross-sectional study, single genome amplification (SGA) was used to sequence 717 full-length HIV-1
envelope (env) clade B variants from the paired cerebrospinal fluid (CSF) and blood plasma samples of fifteen
chronically infected HIV-positive individuals with normal neurocognitive performance (NCN), ANI and MND. Various
degrees of compartmentalization were found across disease states and history of cART utilization. In individuals with
compartmentalized virus, mean HIV-1 env population diversity was lower in the CSF than plasma-derived variants.
Overall, mean V1V2 loop length was shorter in CSF-derived quasispecies when compared to contemporaneous plasma
populations, and this was found to correlate with a lower mean number of N-linked glycosylation sites in this region. A
number of discrete amino acid positions that correlate strongly with compartmentalization in the CSF were identified
in both variable and constant regions of gp120 as well as in gp41. Correlated mutation analyses further identified that
a subset of amino acid residues in these compartmentalization “hot spot” positions were strongly correlated with one
another, suggesting they may play an important, definable role in the adaptation of viral variants to the CSF. Analysis of
these hot spots in the context of a well-supported crystal structure of HIV-1 gp120 suggests mechanisms through
which amino acid differences at the identified residues might contribute to viral compartmentalization in the CSF.
Conclusions: The detailed analyses of SGA-derived full length HIV-1 env from subjects with both normal neurocognitive
performance and the most common HAND diagnoses in the cART era allow us to identify novel and confirm previously
described HIV-1 env genetic determinants of neuroadaptation and relate potential motifs to HIV-1 env structure and
function.
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HIV-1 infection of the central and peripheral nervous
systems (CNS, PNS) can result in a wide range of
pathological and clinical manifestations. These include
HIV-associated encephalopathy, dementia and sensory
neuropathies – all of which contribute significantly to
morbidity and mortality [1-3]. The widespread use of
highly effective combination antiretroviral therapy
(cART) has led to a clear reduction in the incidence of
HIV-associated dementia (HAD), one of the most severe
manifestations of HIV-1 CNS infection [4]. Despite this
decrease, HIV-1 associated neurocognitive disorders
(HANDs) persist in the cART era [5], with an estimated
prevalence of approximately 40-50% [6,7]. Proposed in
2007, current research nosology recognizes three major
categories of disease: asymptomatic neurocognitive im-
pairment (ANI), HIV-associated mild neurocognitive
disorder (MND), and HAD [8]. Asymptomatic neuro-
cognitive impairment is defined as acquired impairment
in at least 2 cognitive ability domains in the absence of
criteria for delirium or dementia, with no other preex-
isting cause in the absence of interference with daily
functioning. Mild neurocognitive disorder shares these
criteria, with the addition of the demonstration of at
least mild interference in daily functioning [8]. When
compared to previous criteria that defined only two
levels of neurologic manifestations of HIV - HAD and
minor cognitive motor disorder (MCMD) - a diagnostic
scheme including ANI was found to have improved
positive predictive power, sensitivity and specificity
when HIV-related brain involvement was defined as the
neuropathological diagnosis of HIV encephalitis (HIVE)
at autopsy [9]. In addition, HIV-1 associated neurocog-
nitive disorders less severe than frank dementia have
been shown to be independently associated with an in-
creased risk for mortality in those with HIV [10] and a
recent study suggests the self-report of functional per-
formance may underestimate symptomatic impairment
in HAND [11].
In the normal state, anatomic, physiologic, and immu-
noregulatory mechanisms ensure the immune privilege
of the brain, preventing recognition of foreign antigens
and diminishing or blocking inflammatory responses
[12,13]. HIV enters the CNS during primary infection
[14,15]. In the “Trojan horse” hypothesis, HIV is postu-
lated to traffic across the blood-brain barrier (BBB) via
the infiltration of infected CD4+ monocytes and perivas-
cular macrophages [16,17]. HIV may also enter the CNS
via infected lymphocytes or as cell-free virus [18,19]. A
recent study by Schnell et al. identified both T cell-tropic
and macrophage-tropic HIV-1 populations genetically
compartmentalized to the cerebrospinal fluid (CSF) of
individuals with HAD [20]. Irrespective of the method of
entry, the infection and activation of monocytes andmacrophages are thought to play an important role in
the pathogenesis of HIVE as well as HAD [21-23]. Dir-
ect neuronal infection of HIV-1 is not believed to occur
[13] and indirect mechanisms inducing neuronal signal-
ing and apoptosis are thought to play a major role in
disease pathogenesis [22,24].
The HIV-1 envelope (env) gene encodes important im-
mune targets and host-range determinants [25]. This
major viral protein mediates binding to the CD4 recep-
tor on target cells, undergoes conformational changes
that allow for viral entry [26] and has been postulated to
play an important role in both neuroinvasion and neu-
rotropism [27]. Genetic differences and phylogenetic
compartmentalization of CNS- and blood-derived partial
HIV-1 env sequences from the same patient have been
documented in several studies [28-32]. Similar analyses
have been performed using full-length HIV-1 env cloned
from individuals with end-stage disease [33]. Analysis of
clonal sequences from chronically infected individuals
have suggested that HIV-1 neurotropism and neuroviru-
lence are modulated by amino acid residues in and
around the V3 loop subregion of the viral envelope, with
the residue at the V3 loop position 5 correlating with
neurocognitive deficit [34]. Several research teams have
proposed CSF signatures or patterns that correlate with
neurocognitive impairment within or in regions adjacent
to the V3 loop [28,29,35,36]. Surface expression of CD4
on macrophages is considerably lower than on CD4+ T
cells [37]. CNS-derived, macrophage-tropic HIV-1 iso-
lates have demonstrated an abilty to infect cells express-
ing low levels of CD4 [38-40], attributed to alterations in
gp120 engagement of the CD4 binding domain [41-43].
Dunfee et al. have previously identified an HIV env
glycoprotein variant in the CD4-binding site of gp120
(N283) present at a high frequency in brain tissues from
AIDS patients with HAD that enhances macrophage
tropism and is associated with brain infection and de-
mentia [44]. There is also evidence that CNS-derived
HIV variants that efficiently infect macrophages may dis-
play greater affinity for the CCR5 HIV-1 co-receptor
[45]. Though controversal, in the context of enhanced
CD4-binding, the ability to utilize lower levels of CCR5
for macrophage entry is postulated to arise from a modi-
fied interaction between gp120 and CCR5 [46-48]. Since
regions outside the V3 loop have been demonstrated to
influence loss of infectivity, host range, and syncytium-
forming ability of T-cell line-tropic HIV-1 recombinant
virus [49], analysis of full-length HIV-1 env sequences
has the potential to reveal novel residues that may con-
tribute to HIV-1 neurotropism.
We hypothesized that full-length HIV-1 env sequence
analysis would allow for the identification of viral char-
acteristics that are distinctly representative of the virus’
localization to the CNS. We describe genetic features of
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ants in the CSF versus plasma, determine shared pat-
terns of CNS compartmentalization of HIV-1 env in a
cohort of individuals with chronic HIV-1 infection, re-
veal the existence of correlated mutation covariation
across full length HIV-1 env and interpret these findings
in the context of current knowledge of the structure of
gp120. We generated viral sequences by single genome
amplification (SGA), whereby PCR products are derived
from a single template molecule, allowing for the most
accurate representation of in vivo HIV-1 quasi-species
for genetic/phylogenetic analysis [50,51]. Investigation of
these parameters across individuals with normal neuro-
cognitive performance (NCN) and importantly, those
with either ANI or MND allowed for the focus on indi-
viduals with the most relevant HAND clinical diagnoses
in the cART era.
Results
Clinical characteristics of the study groups
We obtained clinical samples from fifteen individuals
with chronic HIV-1 infection previously enrolled in
the CNS HIV Antiretroviral Therapy Effects Research
(CHARTER) study. During enrollment in the study,
these individuals underwent comprehensive neurocog-
nitive testing and the Global Deficit Score (GDS)
method was used to classify overall neuropsychological
(NP) impairment status as previously described [52,53].
Validated cutpoints for NP impairment were used to
classify individuals with NCN, ANI and MND. At the
time of neurocognitive testing, contemporaneous cere-
brospinal fluid (CSF) and peripheral-blood samples
were obtained from each individual. De-identified, cryo-
preserved CSF and plasma samples were provided byTable 1 Clinical and demographic profiles for study participa
Participant NCN1 NCN2 NCN3 NCN4 NCN5 NCN6 ANI1
Age 52 41 42 41 45 43 61
Sex M M M M M M M
Race/
Ethnicity
White Black Black White Black White White
Est. Dur. Inf 59.6 173.1 48.9 214.4 75.3 136.9 154.1
ARV Status No ARVs Naïve No ARVs Naïve Naïve No ARVs Naïve
CD4 Count 591 802 687 790 420 418 743
CD4 Nadir 400 554 491 461 297 392 537
Plasma VL 65,600 749 8,620 13,900 19,700 18,900 5,320
CSF VL 120 120 6,600 14,700 18,300 2,910 3,210
RPR Neg Neg Neg Neg Neg Neg Neg
HCV Neg Neg Neg Neg Neg Neg Neg
Participant neurocognitive disease classifications are as follows: NCN = Normal neur
MND =Mild neurocognitive disorder. M =male, F = female. Estimated Duration of In
cells/mm3, plasma and CSF HIV-1 RNA levels (VL) are in copies/mL. RPR = rapid plasCHARTER for this study. Participant demographic and
clinical characteristics are detailed in Table 1.
Given that the ANI and MND diagnoses share their
objective criteria, these two groups were combined for
the purposes of statistical analysis of key demographic
characteristics, and experimental comparisons to indi-
viduals with NCN. All neurocognitive groups were com-
prised of viremic subjects naïve to antiretroviral therapy,
as well as those with a prior history of antiretroviral use
who were not using cART at the time of the study visit
(Tables 1 and 2). The majority of samples were from
white, male participants. The mean age of individuals in-
cluded in this study did not significantly differ amongst
the groups. Groups also did not statistically differ in
their estimated duration of infection, CD4+ T cell
counts, plasma or CSF HIV-1 RNA levels (p > 0.05 for
all comparisons) (Table 2). A CD4+ T cell nadir below
200 cells/mm3 has been statistically correlated with the
onset of neurocognitive impairment [6]. Although the
mean CD4+ T cell nadir was somewhat lower amongst
the ANI and MND group than in individuals without
neurocognitive impairment (333 versus 433 cells/ mm3)
these differences were not statistically significant, and no
individual in this study had a CD4+ T cell nadir below
200 cells/mm3 (Tables 1 and 2). In an effort to exclude
potential confounders that may complicate the interpret-
ation of HAND, cases were not included if it was clinic-
ally probable that neurocognitive impairment or disease
was most likely attributed to co-morbidities other than
HIV infection. As seen in Table 1, samples from individ-
uals without evidence of chronic infection with hepatitis
C as determined by a negative hepatitis C antibody test
at the time of the neurocognitive testing and sample ac-
quisition were chosen for analysis [54]. Additionally,nts
ANI2 ANI3 ANI4 ANI5 ANI6 ANI7 MND1 MND2
51 42 44 37 34 62 40 32
M M M M M M M F
White Black White Hispanic White White Black Black
211.7 46.2 56.2 26.5 59.8 206.6 75.0 58.5
No ARVs Naïve Naïve Naïve No ARVs No ARVs Naïve No ARVs
220 819 237 244 329 466 398 320
220 495 237 244 329 215 398 320
29,800 1,890 38,600 9,210 13,000 50,100 6,250 44,900
5,930 129 1320 653 2430 4,330 454 2,690
Neg Neg Neg Neg Neg Neg Neg Neg
Neg Neg Neg Neg Neg Neg Neg Neg
ocognitive performance; ANI = Asymptomatic neurocognitive impairment;
fection (Est. Dur. Inf) is shown in months. CD4+ T Cell Count (CD4 Count) is in
ma reagin. HCV = hepatitis C virus.
Table 2 Statistical comparison of key clinical and demographic parameters across study groups
Groups NCN ANI +MND p-value
# Male Sex/total 6/6 8/9 N/A
# Men who have sex with men/total 5/6 7/9 N/A
Mean Age (years, range) 44 (41-52) 45 (32-62) 0.72
Mean Years of Education (years, range) 13 (10-16) 14 (9-18) 0.31
Mean Est. duration of infection (months, range) 118 (49-214) 99 (27-212) 0.46
Mean CD4+ T cell count (cells/mm3, range) 618 (418-802) 420 (220-819) 0.09
Mean CD4+ T cell nadir (cells/mm3, range) 433 (297-554) 333 (215-537) 0.15
Mean plasma HIV-1 RNA (log copies/mL, range) 4.3 (2.9-4.8) 4.3 (3.3-4.7) 1.00
Mean CSF HIV-1 RNA (log copies/mL, range) 3.9 (2.1-4.3) 3.4 (2.1-3.8) 0.52
All p-values determined by Mann Whitney test. For all comparisons, p-values <0.05 are considered significant.
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factor of injection drug use (IDU) or evidence of active
syphilis (rapid plasma reagin (RPR) positive) at the time
of sample collection.
Single genome amplification of full length HIV-1
envelope
Single genome amplification of HIV-1 env (>2.5 kb) was
performed on viral RNA from contemporaneous, cryo-
preserved plasma and CSF samples for each individual
using the method of Salazar-Gonzalez et al. [55]. All
study participants were chronically infected with HIV-1
Subtype B virus as determined by the REGA HIV-1 sub-
typing tool [56,57]. A total of 717 confirmed single gen-
ome sequences (SGS) from fifteen (15) patients were
obtained as described in Methods. Consistent with the
absence of contamination between patient samples dur-
ing PCR [58] phylogenetic analysis demonstrates that se-
quences from each patient form tight and distinct
clusters (Figure 1).
Significant HIV-1 env compartmentalization between the
CSF and plasma is seen in a subset of individuals across
neurocognitive disease states and cART status
Phylogenetic analyses of HIV-1 env sequences have doc-
umented distinct viral populations in the CSF and blood
compartments in both primary and chronic infection
[20,34,59]. We therefore sought to identify individuals in
whom genetic characteristics of HIV-1 env quasispecies
in each compartment would allow us to distinguish CSF
from plasma variants by performing formal analyses of
compartmentalization. Nucleotide sequences were ana-
lyzed to increase the sensitivity of identifying genetic
compartmentalization when present and two comple-
mentary methods were used. The multiple-alignment
based, nonparametric test for panmixia [60] was derived
from a geographic subdivision detection test proposed
by Hudson et al. [61]. The phylogenetic-tree based
Slatkin-Maddison (SM) test was used as a second,confirmatory test to infer true shifts in population struc-
ture in a sample [62] as implemented in HyPhy [63]. To
avoid bias in the determination of compartmentalization,
duplicate sequences within each compartment and se-
quences with statistical evidence of G-A hypermutation
were removed from each patient’s dataset prior to analysis.
In this cohort, 3 of 6 (50%) individuals with NCN and 5 of
9 (56%) with ANI or MND demonstrate statistical evi-
dence of compartmentalization. When examined based on
antiretroviral therapy treatment history, it is also apparent
that compartmentalization of virus in the CSF can been
seen in patients that are both naïve to cART (3/8) as well
as those with prior treatment histories (5/8). Representa-
tive individual phylograms are shown in Figure 2 and the
results of formal compartmentalization analysis for all
studied subjects are shown in Table 3.
CCR5-tropic virus predominates in the CSF and plasma in
the majority of HIV-1+ individuals with varying degrees
of neurocognitive impairment
The majority of CNS-derived HIV-1 strains use the che-
mokine CCR5 (R5) as the coreceptor for entry into mac-
rophages and microglia [45,64]. HIV-1 strains able to
use both CCR5 and CXCR4 for cellular entry (so-called
dual-tropic or R5X4 strains) have less frequently been
identified in the brains of some individuals [38,65].
We therefore hypothesized that the majority of SGA-
derived HIV-1 env variants in the CSF and plasma of in-
dividuals with NCN, ANI and MND would exhibit
CCR5 tropism, anticipating a minority of variants pre-
dicted to use CXCR4. Translated V3 loop sequences
were scored using Geno2Pheno [66] and the SINSI
position-specific scoring matrix [PSSM] prediction al-
gorithm [67]. A Geno2Pheno false-positive rate (FPR)
(1-specificity) of 5% was chosen based on reports using
similar FPRs to derive co-receptor predictions that
when compared with results from the Monogram Tro-
file assay, resulted in similar clinical response rates to
the CCR5 inhibitor maraviroc [68]. PSSM has a reported
Figure 1 Intra-Patient Clustering of HIV-1 env quasi-species. Maximum Likelihood (ML) topology view tree depicting full-length HIV-1 env
sequences from fifteen experimental subjects is shown. For each subject, all sequences from both compartments (plasma and CSF) are shown.
Each subject forms a tight cluster and is distinct from other experimental subjects with aLRT SH-like supports >95% for all inter-subject clusters.
HXB2 was used as an outgroup.
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of CXCR4 usage [67].
CCR5-tropic virus was found to predominate in the
CSF and plasma in the majority of HIV-1+ individuals
studied, irrespective of neurocognitive disease classifica-
tion (Table 4). In general, co-receptor tropism classifica-
tions were in agreement using the two methods.
Concordant results using both methods identified rare
instances of variants with a predicted ability to use
CXCR4 in the plasma of two individuals with ANI
(ANI1 and ANI2). Discordant results for participant
ANI7 suggest infrequent (PSSM) or no (Geno2Pheno)
CXCR4-using variants in the CSF and plasma. Interest-
ingly, we were never able to identify CXCR4-using vari-
ants in the CSF in the absence of similarly classified
plasma variants although the reverse was true. Patient
ANI3 was found to have a predominance of variants
with predicted ability to use CXCR4 in both the CSF
and plasma. Genotypic changes allowing the virus to use
CXCR4 have been associated with the more rapidprogression of HIV-1 disease [69]. However, the extent
to which the predominance of CXCR4-using virus in this
individual with a well-preserved CD4+ T cell count, rela-
tively low CSF and plasma HIV-1 viral load (Table 1)
and no evidence of compartmentalized virus may have
influenced their neurocognitive status is unclear.
Amino acid diversity is lower across compartmentalized
CSF-derived full-length HIV-1 env
The blood-brain barrier (BBB) plays a critical role in
preserving immune privilege in the CNS [70] and prior
studies using partial HIV-1 env have found lower viral
sequence diversity in the CSF compared to plasma
[34,71]. We therefore hypothesized that full-length HIV-
1 env amino acid diversity would be lower in CSF-
derived quasispecies when compared to their plasma
counterparts. The generation of multiple single genome
HIV-1 env variants from each compartment allowed us
to look specifically at the amino acid population diver-
sity present in paired plasma and CSF compartments.
Figure 2 HIV-1 env phylogenies - Varying degrees of intra-patient sequence diversity and compartmentalized virus across disease
states. Representative ML trees of SGA sequences from select participants. For all panels, CSF (closed blue squares) and plasma (closed red
circles) are shown. aLRT SH-like supports were determined and values over 85% are shown. HIV-1 env sequences with statistical evidence of
hypermutation were excluded. All scale bars represent 0.005 nucleotide substitutions per site. HXB2 was used as an outgroup. * = Phylogram with
statistical evidence of viral compartmentalization.
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tient sequences after the exclusion of variants with stat-
istical evidence of hypermutation, mean average pairwise
distances (APD) were determined for each quasispecies
of interest, providing a measure of population diversity.
Mean HIV-1 env population diversities in both the CSF
and plasma compartments were consistent with chronic
HIV infection. Irrespective of neurocognitive disease
classification, in the group of individuals with evidence
of compartmentalized viral variants in the CSF (n = 8),
in paired observations, mean diversity of CSF quasispe-
cies was significantly lower than that seen in plasma col-
lected at the same time point (3.34% vs. 5.12%, p = 0.04)
(Figure 3B). In the absence of compartmentalization,
these differences are not statistically significant (3.63%
vs. 4.40%, p = 0.33) although this study is not powered to
detect small magnitude differences (Figure 3A). We were
similarly interested in investigating differences betweenthe level of quasispecies diversity in the CSF and plasma
across disease states. For these analyses, we compared
individuals with NCN (n = 6) to individuals in the neuro-
cognitively impaired (ANI and MND) groups combined
(n = 9). Mean HIV-1 env population diversities were not
statistically different between individuals with NCN and
those with ANI +MND in either compartment (4.02%
vs. 3.37%, p = 0.53 in CSF and 4.44% vs. 4.38%, p = 0.95
in plasma) (Figure 3C-3D).
While not true for all individuals, it is often observed
that measured HIV-1 RNA levels in the CSF are anywhere
from 1-2 log10 lower than those measured in contempor-
aneous plasma [72,73]. In an attempt to determine if the
differences observed in genetic diversity (APD) of the
paired CSF and plasma compartments in the group was
simply a refection of differences in HIV-1 RNA levels
(VL) within the compartments, linear regression analysis
comparing the ratio of each individuals’ plasma to CSF
Table 3 HIV-1 env compartmentalization between the CSF and plasma is seen in a subset of individuals across disease
states
Participant Panmixia Slatkin-Maddison #CSF Sequences #Plasma Sequences
NCN1 0.5820 0.4585 7 20
NCN2 0.0486 0.0672 29 23
NCN3* <0.0001 0.0002 23 27
NCN4* <0.0001 <0.0001 35 19
NCN5* 0.0027 0.0066 27 19
NCN6 0.0011 0.1336 18 15
ANI1* <0.0001 <0.0001 28 25
ANI2* <0.0001 <0.0001 19 21
ANI3 0.3260 0.4889 12 17
ANI4 0.3840 0.1073 24 41
ANI5 0.0032 0.0821 22 19
ANI6* <0.0001 <0.0001 30 28
ANI7* <0.0001 <0.0001 31 23
MND1 0.2010 0.5451 20 26
MND2* <0.0001 <0.0001 26 29
Panmixia and Slatkin-Maddison (SM) probabilities are shown for each study patient. #CSF and #Plasma Sequences = number of sequences used in analysis after
exclusion of hypermutated sequences. For probability of panmixia and Slatkin-Maddison test, p-values <0.05 are considered significant. Starred patients (*) are
those with statistically compartmentalized virus using both methods.
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performed. Linear regression analysis revealed the
absence of any significant correlation between the two
ratios (r2 = 0.10, p = 0.24), suggesting that factors other
than HIV-1 VL are responsible for the observed genetic
divergence between paired CSF and plasma compartments
in this study (Additional file 1: Figure S1).
Variation in the degree of genetic divergence between
CSF and plasma variants across full length HIV-1 env
HIV-1 env consists of variable and constant regions, so
termed because of the level of genetic variation within
the region [74]. In Figure 4A, average genetic diversity
within CSF and plasma populations as measured by
APD in amino acid alignments are shown. Irrespective
of disease classification, in individuals with evidence of
viral compartmentalization (n = 8), a consistent trend to-
wards lower genetic diversity in the CSF compared to
paired plasma variants was seen in the variable regions
of HIV-1 env as well as in the C3 region (Figure 4A).
These differences were not, however, statistically signifi-
cant when applying a stringent correction for multiple
testing (Bonferroni adjusted p-value threshold of p = 0.005).
As expected, in individuals without evidence of viral
compartmentalization (n = 7), the trend towards de-
creased CSF genetic diversity was largely absent,
reflecting the more equilibrated viral populations in
these individuals (Figure 4B). In Figure 4C, mean APDs
between CSF and plasma populations in individuals
with evidence of viral compartmentalization are shown.While mean differences in genetic diversity between the
CSF and plasma compartments (groups) are generally
highest in the variable regions of HIV env, measurable dif-
ferences in APD between compartments are also seen in
the C3 region. In Figure 4D, the mean APD between the
CSF and plasma compartments of individuals without
evidence of compartmentalized virus again demonstrate a
blunting of the between group distances, consistent with
equilibrated virus. However, even in individuals without
evidence of compartmentalized virus, the mean APD be-
tween compartments in the V1V2, V3, C3, V4 and V5
regions suggests that while generally equilibrated, across
HIV-1 env, some CSF variants in these individuals contain
residues that allow for their discrimination from their
plasma counterparts.
Statistically significant differences in the V1V2 loop
length are seen in the CSF and plasma variants and
correlate with differences in the number of potential
N-linked glycosylation sites across the region
In vivo, the HIV env glycoproteins are the primary targets
for neutralizing antibodies [75]. The surface proteins of
HIV-1 are highly variable and highly glycosylated [76] and
N-linked glycosylation on the HIV-1 env glycoprotein is a
major mechanism for minimizing the virus neutralizing
antibody response [77].
We therefore hypothesized that on average, CSF-
derived variants would exhibit shorter V1V2 lengths and
lower degrees of N-linked glycosylation than their paired
plasma counterparts. To determine differences in V1V2
Table 4 CCR5-tropic virus predominates in the CSF and plasma in the majority of HIV-1+ individuals with varying
degrees of neurocognitive impairment
Participant Compartment G2P CCR5 G2P CXCR4 PSSM CCR5 PSSM CXCR4 No Prediction
NCN1 CSF 7 0 7 0 0
Plasma 20 0 20 0 0
NCN2 CSF 29 0 29 0 0
Plasma 23 0 23 0 0
NCN3 CSF 26 0 26 0 0
Plasma 29 0 29 0 0
NCN4 CSF 35 0 35 0 0
Plasma 22 0 22 0 0
NCN5 CSF 28 0 28 0 0
Plasma 21 0 21 0 0
NCN6 CSF 18 0 18 0 0
Plasma 17 0 17 0 1 G2P + PSSM (Ins)
ANI1* CSF 28 0 28 0 0
Plasma 23 2 23 2 0
ANI2* CSF 20 0 20 0 0
Plasma 20 1 20 1 0
ANI3* CSF 0 12 0 12 0
Plasma 1 16 1 16 0
ANI4 CSF 24 0 24 0 0
Plasma 40 0 41 0 1 G2P (Del)
ANI5 CSF 22 0 22 0 0
Plasma 19 0 19 0 0
ANI6 CSF 30 0 30 0 0
Plasma 27 0 28 0 1 G2P (Del)
ANI7* CSF 31 0 29 2 0
Plasma 23 0 22 1 0
MND1 CSF 20 0 20 0 0
Plasma 26 0 26 0 0
MND2 CSF 26 0 26 0 0
Plasma 29 0 29 0 0
The number of translated V3 loop sequences predicted to be CCR5 and CXCR4-tropic using both the Geno2Pheno (G2P) and the SINSI position-specific scoring
matrix (PSSM) for all sequenced viral variants are shown. Three sequences yielded invalid predictions on co-receptor usage as a result of insertions (Ins) or deletions
(Del) in the translated V3 loop sequence. Individuals for whom CXCR4-tropic variants are predicted in the CSF or plasma compartments are starred (*).
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translated amino acid alignments were generated for
each individual (n = 15). With the exception of those
with evidence of G-A hypermutation, all patient-derived
SGS were included in the analysis. Once aligned, the
V1V2 region (amino acids corresponding to positions
131-196 relative to HIV-1 gp160 start in HXB2) was ex-
tracted for analysis. The mean amino acid length for all
V1V2 variants was determined for each patient in the
CSF and corresponding plasma compartment using
MEGA [78]. As shown in Figure 5A, V1V2 loop lengths
were significantly shorter in CSF than paired plasma var-
iants (71.1 vs. 73.6, p = 0.01) across neurocognitivedisease states. No difference was found in the V1V2 loop
length of CSF variants from individuals with NCN when
compared to individuals with ANI or MND (70.3 vs.
71.6, p = 0.84) (Figure 5D). The N-Glycosite program
[79] was then used to identify PNLGS across HIV-1 env
V1V2. In paired comparisons between CSF and plasma
derived variants, the mean number of PNLGS was statis-
tically lower in the CSF (6.2 vs. 6.8, p = 0.04) (Figure 5B).
Linear regression analysis revealed a significant positive
correlation between the V1V2 length in CSF variants
and the mean number of PNLGS sites therein (p = 0.02)
(Figure 5C). The linear regression score (r2 = 0.34) sug-
gests a mild relationship, with approximately 34% of the
Figure 3 Mean population amino acid diversities across HIV-1 env. Mean Average Pairwise Distance determinations between the (A) paired
CSF and plasma HIV-1 env variants of all participants (n = 15) and (B) CSF and plasma HIV-1 env variants of participants with statistical evidence of
CSF viral compartmentalization (n = 8) (C) CSF of individuals with NCN (n = 6) and those with neurocognitive disease (ANI + MND) (n = 9) and
(D) plasma of individuals with NCN (n = 6) and those with ANI or MND (n = 9). All calculations were performed after the exclusion of sequences
with statistical evidence of hypermutation. The Wilcoxon matched-pairs signed rank test and the Mann Whitney test were used to determine p-values
for paired observations (CSF vs. plasma) and observations between disease classifications (NCN vs ANI +MND) respectively. APD = Average Pairwise
Distance. For all comparisons, p-values <0.05 are considered significant. * = Statistically significant
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ation in V1V2 loop length.
Molecular patterns of compartmentalized HIV-1 env
reveal genetic signatures of CNS adaptation
We hypothesized that full-length HIV-1 env sequence
analysis would identify sites in amino acid alignments that
are distinctly representative of the virus’ localization to the
CNS and that the use of SGA-derived full-length HIV-1
env would allow for the greatest accuracy and breadth of
these analyses. The goal of these analyses was to identify
positions in each individual along HIV-1 env that were se-
lected with a high degree of statistical significance for
compartmentalization. This would then allow us to deter-
mine if particular amino acid residues were favored for
compartmentalization across individuals. Single genome
sequences from all 15 individuals in the study were
grouped into one master alignment containing the HXB2
HIV-1 env reference sequence, which was then translated
in frame, resulting in an amino acid alignment. As was
done for determinations of compartmentalization, dupli-
cate sequences within individual patient compartmentswere removed from the analysis in an attempt to limit bias
resulting from the analysis of clonally derived sequences.
Sequences with evidence of statistically significant G-A
hypermutation were also excluded. All non-HXB2 sites
were removed from the alignments. For each individual,
signature pattern analysis was performed using the Viral
Epidemiology Signature Analysis (VESPA) software [80].
The VESPA software examines amino acid differences be-
tween groups of sequences (CSF SGS and plasma SGS).
Positions where the dominant amino acid in the CSF
alignment (query) was different than the dominant amino
acid in the plasma alignment (background) were identi-
fied. A fisher’s exact test was then performed for each site
to determine locations across HIV-1 env where statistically
significant differences were noted in the CSF versus dom-
inant plasma residue. A Bonferroni correction for multiple
comparisons was performed for each participant’s align-
ment where the number of variable sites in their individ-
ual HIV env alignment was used to determine the
correction. The number of individual SGS included in
each alignment, variable sites per patient alignment calcu-
lated in MEGA [78], and the corresponding corrected
Figure 4 Variation in amino acid genetic diversity across HIV-1 env. Box plots displaying Mean Average Pairwise Distances (APD) between
the (A) paired CSF (red) and plasma (black) variants of subjects with statistical evidence of CSF viral compartmentalization (Compart.) across all
regions of HIV-1 env (n = 8) and (B) paired CSF (red) and plasma (black) of variants of subjects without statistical evidence of CSF viral
compartmentalization (n = 7). In panel (C) the Mean Between Group (CSF vs. Plasma) APD is shown for subjects with statistical evidence of CSF
viral compartmentalization across all regions of HIV-1 env (n = 8) and in (D) the Mean Between Group (CSF vs. Plasma) APD is shown for subjects
without statistical evidence of CSF viral compartmentalization across all regions of HIV-1 env (n = 7). All calculations were performed after the
exclusion of sequences with statistical evidence of hypermutation. The Wilcoxon matched-pairs signed rank test was used to determine p-values
for paired observations. APD = Average Pairwise Distance. For all comparisons, p-values <0.05 are considered significant. * = Statistically significant.
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in tabular form as Additional file 2: Table S1. P-value
thresholds ranged from p < 7×10-4 to p < 2×10-4.
In an attempt to exclude positions for which uncer-
tainties in the multiple alignments might impact the re-
sults, we employed the GUIDANCE web-server [81].
Using bootstrap trees as guide-trees to the alignment al-
gorithm, the GUIDANCE program constructs a set of
multiple sequence alignments, measures the robustness
of the alignment to guide-tree uncertainty and compares
them to the base alignment in order to estimate its con-
fidence level. In this way the tool identifies columns that
are unreliably aligned, enabling their removal from thealignment. This comparison results in scores between 0-
1 for each column of the multiple sequence alignment.
Columns with a GUIDANCE score below 0.9 were ex-
cluded from further analysis. All reported amino acid
positions are represented in a minimum of two inde-
pendent participant alignments with a high degree of
statistical significance.
Figure 6A displays the compartmentalization hot
spots identified along the full-length HIV env. As would
be expected, while compartment discriminating posi-
tions can be seen in some individuals with non-
compartmentalized (equilibrated) virus, none of these
positions met statistical significance as defined above.
Figure 5 V1V2 loop length and N-linked glycosylation (CSF vs Plasma). The mean (A) amino acid lengths and (B) number of potential
N-linked glyosylation sites (PNLGS) of the HIV-1 env V1V2 region from paired CSF and plasma quasispecies are shown for all subjects (n = 15).
(C) Linear regression of the mean amino acid lengths of the HIV-1 env V1V2 region from CSF quasispecies with the corresponding mean number
of PNLGS in the same quasispecies. (D) The mean amino acid lengths of the HIV-1 env V1V2 region in the CSF quasispecies of individuals with
NCN and those with ANI + MND. The Wilcoxon matched-pairs signed rank test and the Mann Whitney test were used to determine p-values for
paired observations (CSF vs. plasma) and observations between disease classifications (NCN vs ANI + MND) respectively. The linear regression score
(r2) was derived in PRISM. For all comparisons, p-values <0.05 are considered significant. * = Statistically significant.
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gion is a reflection of the removal of uncertain columns
in the master alignment. The majority of reported hot
spot sites were shared by a maximum of two individuals
in the study, representing 25% of individuals with com-
partmentalized virus (n = 8). Amino acid signature pat-
tern analysis identified two CSF-specific residues in 3/8
compartmentalized individuals (37.5%), C2 position 97
(HXB2 gp160 position 293) and V3 position 13 (HXB2
gp160 position 308). Several researchers have reported
the overrepresentation of particular amino acids at one
or both of these positions in CSF-derived variants
[28,30,34]. It is important to note that overall, amongstthe 20 robust discriminating positions identified in the
external glycoprotein gp120, we report several novel
sites, particularly those outside of the C2-C3 region. An
additional 5 novel positions are reported in the trans-
membrane glycoprotein gp41.
A subset of amino acid residues that correlate with CSF
compartmentalization are statistically correlated to one
another
We further hypothesized that amino acids at a subset of
these compartmentalization hot spots might mutate co-
ordinately. Our derivation of full-length HIV-1 env CSF
variants derived from single genomes allowed us to test
Figure 6 Compartmentalization “Hot spots” across full-length HIV-1 env and the network of correlated mutations. Results of analyses
identifying compartmentalization hot spots (A). All positions listed are significant in ≥ 2 individuals. Subjects with statistically non-compartmentalized
(blue) and compartmentalized (yellow) CSF quasispecies are shown. For each hot spot, corresponding HXB2 gp160 (white) and specific gene-region
(C1-gp41) numbering (red) is shown (regions not drawn to scale). Amino acids at hot spot positions in CSF (C) alignments meeting the threshold for
statistical significance are shaded in purple. Corresponding plasma (P) amino acids are shown directly below. (B) An adjacency matrix demonstrating
hot spot positions with amino acids sharing statistically significant mutual information (MI) in ≥ 2 subjects. Lines connect positions sharing MI, with the
thickness of the line corresponding to the number of studied subjects in which the correlation was identified. Surface representation of the hot spots
on a gp120 trimer based on the SOSIP crystal structure in a side (C) and top (D) view. The three gp120s in the trimer were rendered as surfaces and
colored light grey, grey and blue, respectively. For simplicity, the hot spot residues were colored individually and only displayed in one of the gp120s
(light grey). A CD4 molecule (with N-terminal D1D2 domains; cyan ribbon) was placed onto this gp120 by superimposition of its complex with a
gp120 core to indicate the location of the CD4 binding site (light red). The entire V1V2 region and V3 region are colored light green and light orange,
respectively, while the hot spots are colored more intensely. Note that the hot spot residues form several spatial clusters on the gp120 surface,
including the V2 tip region (dark green), V3 region (dark orange), the CD4 binding site proximal region (red), the outer domain cluster (blue) and the
inner domain cluster (pink).
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Table 5 The network of correlated mutations in
compartmentalization hot spot positions across
HIV-1 env
aa1 aa2 Patients
225 (C2 29) 300 (V3 5) NCN4, ANI1
290 (C2 94) 389 (V4 5) NCN4, MND2
293 (C2 97) 337 (C3 6) NCN4, ANI6
300 (V3 5) 535 (gp41 24) NCN2, ANI1
300 (V3 5) 641 (gp41 130) NCN2, ANI1
305 (V3 10) 362 (C3 31) NCN4, NCN5
305 (V3 10) 724 (gp41 213) NCN4, NCN5
336 (C3 5) 337 (C3 6) NCN3, ANI2, MND1
337 (C3 6) 362 (C3 31) NCN4, MND1
346 (C3 15) 620 (gp41 109) ANI1, ANI7
362 (C3 31) 389 (V4 5) ANI1, MND1, MND2
362 (C3 31) 392 (V4 8) NCN5, ANI1
362 (C3 31) 724 (gp41 213) NCN4, NCN5
389 (V4 5) 462 (V5 3) ANI4, MND1, MND2
462 (V5 3) 463 (V5 4) ANI2, MND1
535 (gp41 24) 641 (gp41 130) NCN2, ANI1
Compartmentalization Hot spots with amino acids sharing mutual information
(MI) in ≥ 2 subjects, an MI value of ≥ 0.10 and a Benjamini–Hochberg adjusted
p-value for the correlation < 0.05. HXB2 gp160 numbering for amino acids (aa1
and aa2) followed by corresponding gene-region specific amino acid positions
are shown.
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functions for detecting correlated mutations among
specific amino acids [82]. This package was used to com-
pute correlations among the amino acids in the CSF
compartmentalization hot spot sites identified in the study
cohort. Similar to the analyses of compartmentalization
sites, correlation mutation analyses were performed inde-
pendently for each individual in the study using the partic-
ipants’ own codon-aligned plasma consensus sequence
(derived from their plasma SGS variants) as a comparator
to their multiple, codon-aligned CSF-derived SGS variants.
For each individual, positions under consideration were
restricted to those previously identified as being statisti-
cally significantly selected in CSF compartmentalization.
This method allowed for the determination of CSF hot
spot mutations sharing mutual information within each
individual. In correlation analyses, the mutual information
score (MI) expresses the measure of the strength of asso-
ciation between the two positions. An MI score of 0 sug-
gests that the two positions are independent and that
information in one position provides no information
about the other. An MI score of 1 suggests that all infor-
mation conveyed by one position is shared with the other.
For these analyses, an MI score threshold of 0.10 was
chosen. As an additional criteria, mutations were consid-
ered significantly correlated if the Benjamini–Hochberg
adjusted p-value for the correlation was less than 0.05
(corresponding to a 5% false discovery rate). Finally, as
with the compartmentalization analyses, all reported cor-
related mutations were identified in at least 2 independent
observations (study individuals) in an attempt to increase
the chance that reported associations were the result of
immune pressure as opposed to resulting from founder ef-
fect. The network of correlated mutations, number of in-
dividuals sharing the correlation and complete listing of
amino acids in each pair of sites exhibiting mutual infor-
mation are displayed in Figure 6B, Table 5, and Additional
file 3: Dataset S1. Correlation between C3 position 5
(HXB2 gp160 336) and C3 position 6 (HXB2 gp160 337),
C3 position 31 (HXB2 gp160 362) and V4 position 5
(HXB2 gp160 389), and V4 position 5 (HXB2 gp160 389)
and V5 position 3 (HXB2 gp160 462) were the most-often
identified correlations, each noted in 3 of 15 (20%) indi-
viduals studied. While these short-range correlations are
most expected, this analysis also reveals significant correl-
ation between amino acid positions in V3 and gp41, as
well as positions in C3 and gp41. The V3 position 5
(HXB2 gp160 300) was found to share a significant degree
of MI with three other positions; C2 position 29 (HXB2
gp160 225) and gp41 positions 24 and 130 (HXB2 gp160
535 and 641). C3 position 31 (HXB2 gp160 362) was
found to share significant MI with 5 other hot spot posi-
tions, the greatest number identified in this analysis. In
contrast, a number of positions statistically linked to CSFcompartmentalization in at least 2 individuals were not
found to covary significantly with any of the other such
identified positions in at least 2 individuals studied. These
positions include those closest to the N-terminus of gp160
(C1 position 85, V2 positions 164 and 166).
3D spatial relationships of the compartmentalization hot
spot positions in the HIV-1 env trimer
To gain a functional understanding of the compart-
mentalization hot spots, we projected these positions
onto the recently published crystal structure of the
SOSIP trimer, which is a stabilized gp140 crystallized in
complex with the Fab of PGT122 [83]. Due to the lim-
ited resolution of the structure, only residues in gp120
were identified (Figures 6C and 6D). The hot spot resi-
dues can be naturally grouped into several spatial clus-
ters: (1) The V2 tip cluster (residues 164 and 166); (2)
the V3 cluster (residues 300, 305, 308, and 316); (3) the
cluster proximal to the CD4 binding site (residues 362,
389, 392, 462, and 463); (4) the inner domain (residue
85 and 225); (5) and outer domain (residues 268, 290,
293, 332, 336, 337, and 346) clusters. These 5 clusters
are likely also functionally distinct. The residues in the
V2 tip cluster are located at the tip of the strands B and
C of V1V2 [84] which is packed against the other 2 mol-
ecules in the trimer (trimer association), thus they will
likely play a role in the trimer formation. The residues
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fluence the interaction with V1V2. They may also be in-
volved in co-receptor binding. Although the cluster
proximal to the CD4 binding site does not overlap with
the CD4 binding site, it is next to it and will likely influ-
ence CD4 binding site formation. The inner domain
cluster has only two residues; one (residue 85) located
on the inner domain surface and the other (residue 225)
buried in the core. Residues in this domain have been
shown to influence the layer formation of gp120 [85]
thus the inner domain cluster can play similar roles.
The outer domain cluster is the largest cluster of the
hot spot residues and is located on the other side of the
CD4 binding site. As the majority of CD4 binding resi-
dues are in the outer domain of gp120, it is conceivable
that changes in residues in this cluster situated on the
back of the outer domain may influence the formation
of the CD4 binding site.
Discussion
Combination antiretroviral therapy (cART) has become
the standard of care for the treatment of HIV-1 infec-
tion, and can effectively and persistently suppress viral
replication, as reflected by the reduction of plasma HIV-
1 RNA to levels below detection in adherent patients. As
such, progression of HIV infection to AIDS and death
have been dramatically reduced with a considerable de-
crease in morbidity [86,87]. Similarly, the widespread
use of cART has also led to a clear reduction in the inci-
dence of HIV-associated dementia (HAD), one of the
most severe manifestations of HIV-1 CNS infection.
Despite this decrease, the prevalence of less severe HIV-
1 associated cognitive impairment appears to be on the
rise [8,88,89].
HIV-1 exhibits significant genetic diversity that is not
equally distributed across the genome [90]. The most dra-
matic features of variability are localized to the viral env
gene, particularly the five variable regions of gp120 (V1-
V5) [91]. In this study we have performed a detailed com-
parative genetic examination of the distinct mutational
patterns exhibited by HIV-1 env variants in the plasma
and CSF of fifteen individuals chronically infected with
HIV-1 Subtype B. In the analyses, cerebrospinal fluid
(CSF) virus was used as an investigative surrogate for
brain-derived HIV-1. Although indirect, this strategy is
validated by phylogenetic evidence that CSF and brain-
derived viral populations are more closely related to each
other than to populations derived from other body com-
partments [92]. We hypothesized that detailed analyses of
full-length HIV-1 env (>2.5Kb) would allow for the identi-
fication of genetic characteristics associated with the pres-
ence of viral variants in the CNS. We analyzed 717
confirmed single genome sequences (SGS) and demon-
strate that measurable variation exists in the degree ofgenetic divergence between CSF and plasma variants
across full length HIV-1 env, various degrees of
compartmentalization between the CSF and plasma var-
iants exist across neurocognitive disease states and in
individuals with compartmentalized virus, mean HIV-1
env diversity is significantly lower in CSF- than in
plasma-derived variants.
The antibody response to HIV infection evolves in
concert with viral diversity, resulting in the emergence
of neutralization-resistant HIV variants [77]. Several
studies have found that efficient replication of HIV-1 in
macrophages and microglia correlates positively with in-
creased sensitivity to neutralizing antibodies [41,45,93]
and neurotropic HIV-1 isolates with increased CCR5
affinity have been demonstrated to be more sensitive to
antibody neutralization [41,45]. In comparison to plasma-
derived virus, the extent of N-linked glycosylation across
the C2-V3 env subregion has been shown to trend some-
what lower in viral variants cloned from the CSF [34].
More recently, the neutralization resistance of a reference
panel of tier-categorized neutralization-sensitive and re-
sistant HIV-1 plasma-derived variants has been demon-
strated to correlate with a longer V1V2 loop containing
more potential N-linked glycosylation sites (PNLGS) [94].
When considered in concert with our findings of de-
creased mean diversity in CSF-derived full-length HIV-1
env quasispecies - a finding consistent with prior studies
using partial HIV-1 env [34,71] - our findings that
the mean V1V2 loop length is shorter and the mean
number of PNLGS is lower in CSF-derived variants
compared to their paired plasma counterparts sup-
ports the hypothesis that immune selection pressures
are reduced in this privileged compartment [70]. The
significant positive correlation between V1V2 loop
length and number of PNLGS in CSF variants is evidence
that length variation in the V1V2 loop is a tool for evolu-
tionary selection. The correlation r2 of 0.35 between the
two parameters, however, suggests that the degree of gly-
cosylation seen in this region is not solely the direct reflec-
tion of V1V2 loop length and that other immune factors,
such as potential selection pressures related to macro-
phage tropism, may play an important role. The previous
finding by Drunfee et al. that targeted loss of N-linked gly-
cosylation at position 386 in the V4 region enhances
macrophage tropism and is associated with dementia sup-
port this possibility [95].
Published studies specifically seeking to reveal specific
sites of HIV-1 env that distinguish them from plasma
counterparts have typically been performed using either
the heteroduplex tracking assay (HTA) [31] or bulk and
near-endpoint PCR followed by cloning and sequencing
[34]. The use of SGA allows for a more accurate repre-
sentation of in vivo CSF specific HIV-1 quasi-species.
Using this method, we took a unique approach to the
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phylogenies where the dominant amino acid differs sig-
nificantly between CSF and plasma quasispecies in both
variable and constant regions of gp120 as well as in
gp41. Comparing positions across individuals, we identi-
fied 25 compartmentalization hot spots across the full-
length envelope gene. These include multiple novel
positions in HXB2 gp160, including those at 463 (V5 4)
and 535 (gp41 24) as well as at the previously identified
position 308 (V3 13), which has been reported in several
studies identifying compartmentalization sites using con-
sensus population sequences [28,30,34]. In addition, the
presence of certain residues at position 308 has been as-
sociated with macrophage tropism [96] and dementia in
studies of autopsy brain samples from those with HIV
[29]. The presence of a hot spot at position 362 (C3 31)
is noteworthy, as this potential N-linked glycosylation
site (N362) seen here in the plasma of two individuals
with compartmentalized virus has been shown to con-
tribute to enhanced fusogenicity in HIV-1 env variants
from patients with AIDS [97]. With the exception of the
V1, C4 and C5 regions, multiple positions that discrim-
inate CSF and plasma SGS populations in more than
one studied individual can be found throughout the vari-
able and constant regions of the receptor binding do-
main gp120 and the fusion protein subunit gp41 which
work in concert to catalyze virus entry [98].
The evolution of amino acid sequences is naturally
constrained by the need to maintain protein structure
and function [99]. The interpretation of correlated muta-
tional behavior (the tendency of amino acid positions in
a protein to mutate coordinately) therefore allows for
the inference of potential physical or functional inter-
action [100]. The identification of such correlated substi-
tutions of amino acids has been applied in several
instances to identify mutational clusters in HIV-1 re-
verse transcriptase and protease in response to ART
[101-104] and to identify gp41 mutations that are signifi-
cantly associated with particular HIV-1 V3 signatures
that influence co-receptor usage [105]. We hypothesized
that correlation analyses of amino acid positions in
SGA-derived full-length HIV-1 env CSF variants would
identify positions that share mutual information. In this
study, novel correlated mutation analyses reveal that a
subset of the amino acid residues identified in the initial
compartmentalization hot spot positions form a network
of significant correlations, with mutual information
scores ≥ 0.10. We posit that these novel findings, made
possible by the sequencing of full-length HIV-1 env,
could provide potentially high-yield targets for down-
stream investigation of the implications of amino acid
identity on the ability of the virus to persist in the CSF
microenvironment, potentially via the infection of and
enhanced replication in the various subtypes of CNS-resident macrophage and macrophage-type cells or
microglia.
Structural mapping of the hot spot positions identified
in this study onto the recently published SOSIP trimer
structure revealed that these hot spots could be grouped
into distinct spatial and functional clusters. This analysis
suggested that these hot spot residues are located in re-
gions potentially involved in trimer and CD4 binding site
formation, and co-receptor binding. While entry of these
viruses into the CSF via T-cells or as cell-free virus can-
not be excluded, these data are consistent with the hy-
pothesis that the CSF compartmentalized viruses are
adapted for entry into CNS target cells and residency in
the immune privileged CNS allows residues at these
clusters to persist distinct from those in the plasma. For
example, the V2 tip cluster is located at the apex center
of the gp120, and alteration of these residues can
destabilize the trimer, potentially allowing easier access
to the CD4 bound conformation and the co-receptor
binding site. Similarly, there are several residues in the
hot spot cluster proximal to the CD4 binding site, and
alteration of these residues may influence the formation
of the CD4 binding site. This finding is of interest, as an
enhanced ability for brain-derived HIV-1 env to use low
levels of CD4 for virus entry in macrophages and micro-
glia has been described [44]. Finally, structural mapping
of the hot spot residues also supports some of the corre-
lated mutation findings. For example, residues 362 and
392 linked in Figure 6B, are spatially next to each other
in the cluster proximal to the CD4 binding site.
One limitation of the present study is the size of the
study cohort. We sought to overcome this limitation by
maximizing the amount and quality of the sequence data
through the use of SGA. In this way we were able to
identify sites where the dominant amino acid discrimi-
nates between CSF and plasma quasispecies within indi-
viduals using stringent statistical thresholds. The value
of this method is seen in our ability to find both previ-
ously identified and novel compartmentalization sites
across full-length HIV-1 env.
In an effort to identify specific HIV-1 env residues sta-
tistically associated with prevalent HAND in the study
cohort, consensus sequences were derived from each in-
dividual’s CSF-variants. However, given the study size, it
was not possible to report a statistically significant differ-
ence in a comparison of consensus sequences from those
with NCN (n = 6) in comparison to those with ANI +
MND (n = 9). Even at sites where the dominant residue
differed completely between the two disease states, the
maximum achievable fisher’s exact p-value of 2.0 × 10-4
would not fall under the Bonferroni corrected p-value
threshold determined for comparison of variable sites
across all 9 consensus sequences (p < 1.24 × 10-4). Lar-
ger studies, in which full-length HIV-1 env sequencing is
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those with NCN and those with both ANI and MND
disease is warranted, particularly as the investigation of
individuals with weaker neurocognitive phenotypes may
make uncovering genetic correlates of disease more diffi-
cult. We were also unable to identify viral genetic char-
acteristics allowing us to discriminate between HIV-1
env quasispecies from individuals with NCN and those
with ANI and MND. Mean viral diversity in both the
CSF and plasma compartments did not differ signifi-
cantly between individuals with NCN and those with
ANI or MND and V1V2 loop length in CSF-derived var-
iants CSF did not differ significantly between individuals
with NCN and those with ANI or MND. The develop-
ment of HAND is likely multifactorial, and the integra-
tion of knowledge about particular host social and
genetic determinants of disease including HLA typing
would be appreciated, but was not feasible within the
confines of this study.
This study presents a cross-sectional analysis of a co-
hort of individuals with and without HAND. While
highly informative, by definition this analysis captures a
static view of the dynamic composite events that lead to
the compartmentalization of virus, adaptation of viral
variants to the CSF and the development of disease in
those eventually diagnosed with HAND. As studies fol-
lowing individuals during primary infection have demon-
strated, compartmentalization of virus to the CSF can be
transient [59]. Additional studies following the specific
genetic characteristics within CSF quasispecies from
primary HIV-1 infection prior to the development
of compartmentalization and/or HAND diagnosis are
needed.
Finally, in interpreting these data, we must also con-
sider the potential influence of the founder effect, par-
ticularly as it relates to the investigation of the described
compartmentalization hot spots and the correlated net-
work of residues at those sites. In an effort to report dis-
criminatory changes that we believe are likely to result
from evolutionary selection, we studied a group of unre-
lated chronically infected participants and restricted our
reported findings to those common to a minimum of
two unrelated individuals. The fact that other re-
searchers using geographically and temporally distinct
cohorts have described a subset of the sites reported in
this study suggest that these changes in HIV-1 env may
largely arise from distinct selective pressures.
Conclusions
Detailed analyses of SGA-derived full length HIV-1 env
from subjects with normal neurocognitive performance and
those with the most common HAND diagnoses in the
cART era allowed us to identify novel and previously de-
scribed HIV-1 env genetic determinants of neuroadaptationand relate potential motifs to envelope structure and
function. We demonstrated significant HIV-1 env
compartmentalization between the CSF and plasma in a
subset of individuals across neurocognitive disease
states and cART status. In individuals with compart-
mentalized virus, mean HIV-1 env diversity was statisti-
cally lower in CSF- than in plasma-derived variants. In
addition, mean V1V2 loop length was shorter and the
mean number of PNLGS was lower in CSF-derived vari-
ants compared to their paired plasma counterparts, sup-
porting the hypothesis that immune selection pressures
are reduced in the privileged CNS compartment. Ana-
lysis of molecular patterns of compartmentalized HIV-1
env quasispecies revealed a series of compartment-
discriminating positions (hot spots) within both variable
and constant regions of HIV-1 env that are shared
across non-related individuals, and a subset of amino
acid residues within these hot-spots are statistically cor-
related to one another, suggesting a shared functional
role. Structural mapping of the hot spot positions iden-
tified in this study suggests that these residues are lo-
cated in regions potentially involved in trimer and CD4
binding site formation, and co-receptor binding. A com-
bination of genetic features likely distinguishes viral
populations compartmentalized to the CSF. The use of
SGA and phylogenetic approaches is an effective method
for identifying genetic features of neuroadaptation within
the HIV-1 env gene and further experimental validation of
predictions arising from these analyses will enable us to
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all non-UCSD sites, the Human Research Protections
Program at each enrolling site approved the research.
All participants in the CHARTER study provided written
informed consent prior to sample acquisition and all
clinical investigation was conducted according to the
principles expressed in the Declaration of Helsinki. The
author’s use of de-identified clinical samples from the
CHARTER study was approved by the Institutional Re-
view Board of the Rockefeller University (New York,
New York, United States).
Study subjects and sample acquisition
Study subjects were chosen from the CHARTER cohort.
De-identified, contemporaneous, cryopreserved CSF
and plasma samples from fifteen chronically infected,
HIV-1 seropositive individuals with normal neurocogni-
tive performance (NCN), Asymptomatic Neurocognitive
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(MND) were provided.
Neurocognitive testing and clinical histories were ob-
tained at CHARTER study visits by trained psychometrists
and research staff. Participants underwent a comprehensive
neurocognitive battery of tests within seven cognitive do-
mains: speed of information processing, learning, recall, ab-
straction/executive functioning, verbal fluency, attention/
working memory and motor skills. Following the demo-
graphic correction of T-scores for each test measure, a glo-
bal deficit score (GDS), based on number and magnitude
of impaired test performances was determined. At the time
of neurocognitive testing, contemporaneous cerebrospinal
fluid (CSF) and peripheral-blood samples were obtained
from each individual by lumbar puncture and routine
phlebotomy. Peripheral blood CD4+ T cell counts were
performed at CHARTER research sites using routine estab-
lished methods. HIV-1 RNA levels in the CSF and plasma
were determined using the Roche Amplicor, version 1.5,
with a lower limit of quantitation of 50 copies/mL.
RNA extraction, generation of cDNA and single genome
amplification
Thawed CSF and plasma samples were centrifuged at
2,500 rpm for 10 minutes to remove any contaminating
cellular debris. HIV-1 in clinical samples was then con-
centrated by centrifugation for 2 hours at 25 K x g.
Supernatant was removed down to 140 μL and the viral
pellet resuspended. Viral RNA from clinical samples was
extracted by routine methods using the QIAamp Viral
RNA Mini Kit (QIAGEN, USA). To minimize the risk of
within-patient cross contamination of samples, only one
participant sample from one compartment (CSF or
plasma) was processed on any given day.
We used published methods for SGA to generate
cDNA and amplify single proviral molecules of full-
length HIV-1 subtype B env gene (>2.5 kb) [55]. Reverse
transcription (RT) of RNA to cDNA was performed
using SuperScript III reverse transcriptase (Invitrogen
Life Technologies, Carlsbad, CA). Briefly, 50 μL of
RNA template, 0.5 mM deoxynucleoside triphosphates
(dNTPs), 0.25uM primer env3out 5′- TTGCTACTTT
GGATTGCTCCATGT-3′, and RNase-free water were
incubated for 5 min at 65°C in a total volume of 65 μL
to denature the secondary structure of the RNA. First-
strand cDNA synthesis was carried out with 10 u/μL
SuperScript III, 1x reverse transcriptase buffer, 2 u/μL
RNase inhibitor (RNaseOUT, Invitrogen Life Technolo-
gies, Carlsbad, CA) and 5 mM DTT. Following reverse
transcription, the reaction mixture was heat-inactivated
followed by RNase H digestion (Invitrogen Life Tech-
nologies, Carlsbad, CA) at 37 degrees Celsius for 20 mi-
nutes. The resulting cDNA was used immediately for
PCR or frozen at 80°C to await further analysis. All RNAextractions and amplification reactions were carried out
with appropriate negative controls in parallel to detect
contamination at each step of the procedure. cDNA was
serially diluted and distributed in replicates of 10 PCR
reactions in MicroAmp 96-well plates (Applied Biosys-
tems, Foster City, CA) and cDNA was endpoint diluted
in 96-well plates such that fewer than 30% of the PCRs
yielded an amplification product. Additional PCR ampli-
fications were performed using this dilution in 96-well
reaction plates. PCR amplification was carried out in
presence of 1x High Fidelity Platinum Taq PCR buffer,
2 mM MgSO4, 0.2 mM each deoxynucleoside triphos-
phate, 0.2 μM each primer, and 0.025 units/ μL of Plat-
inum Taq High Fidelity polymerase in a 20 μL reaction
(Invitrogen, Carlsbad, CA). The nested primers for gen-
erating full-length env were as follows: 1st round sense
primer env5out 5′-TAGAGCCCTGGAAGCATCCAG
GGAAG-3′, 1st round antisense primer env3out 5′-
TTGGCTACTTGTGATTGCTCCATGT-3′, 2nd round
sense primer env5in 5′-TTAGGCATCTCCTATGGCAG
GGAAGAAG-3′ and 2nd round antisense primer env3in
5′-GTCTCGAGATACTGCTCCCACCC-3′. PCR pa-
rameters were as follows: 94°C for 2 min, followed by
35 cycles of 94°C for 15 s, 55°C for 30 s, and 68°C for
4 min followed by a final extension of 68°C for 15 min.
The product of the first-round PCR was used as a tem-
plate in the second-round PCR under the same condi-
tions with the following PCR parameters: 94°C for
2 min, followed by 45 cycles of 94°C for 15 s, 55°C for
30 s, and 68°C for 4 min followed by a final extension of
68°C for 15 min. The resulting amplicons were then
inspected on an E-Gel® 96 2% with SYBR® Safe (Invitro-
gen Life Technologies, Carlsbad, CA). All PCR proce-
dures were carried out under clean PCR conditions with
appropriate negative controls.
DNA Sequencing
HIV-1 env gene products were directly sequenced using
an automated ABI Prism 3730xl DNA analyzer (Applied
Biosystems, Inc.). Both strands of DNA were sequenced
with partially overlapping fragments. All sequencing chro-
matograms were carefully inspected for sites of ambiguous
sequence (double peaks). Sequences for which any chro-
matogram revealed double peaks were excluded from fur-
ther analysis, as this was indicative of amplification from
more than one template or an early taq polymerase error.
Sequence alignments
The CAP3 DNA sequence assembly program was used to
concatenate sequence fragments for each pcr product
[106]. Multiple alignments of nucleotide sequences were
produced using Clustal W [107] with the following param-
eters: pairwise alignment gap opening penalty 10; gap ex-
tension penalty 0.1; multiple alignment gap opening
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tein profile alignments were produced with ClustalX
[107]. All resulting alignments were inspected and edited
the Alignment Explorer in the MEGA 5.2 software when
warranted [78]. Multiple alignments of codon and protein
sequences were produced using Gene Cutter, a sequence
alignment and protein extraction tool on the Los Alamos
HIV database site http://www.hiv.lanl.gov. This algorithm
first codon-aligns the input alignment, then translates the
codon-alignment in frame using Hmmer v 2.32 with a
training set of the full-length genome alignment.
Phylogenetic tree construction and sequence diversity
analysis
Nucleotide-based phylogenetic trees were constructed
by the maximum likelihood (ML) method using the
General Time Reversible plus Gamma (GTR +G) evolu-
tionary model in the PhyML program [108]. Columns
with gaps were removed from the multiple alignments
using GapStrip/Squeeze v 2.1.0 with a gap tolerance of
50% on the Los Alamos HIV database site (http://www.
hiv.lanl.gov) prior to constructing individual patient phy-
lograms. Statistical evaluation of branch support in each
phylogeny was performed using the approximate likeli-
hood ratio test (aLRT) with SH-like supports [109]. The
ProtTest tool was used to determine the most appropri-
ate protein substitution model for data description. The
“distance matrix” calculation in MEGA 5.2 was used to
determine average pairwise genetic distances within or
between compartments [78]. Overall, the phylogenetic
model found to best describe the protein data while allow-
ing for distance matrix calculations to be performed in
MEGA 5.2 was the JTT plus Gamma model [110].
Hypermutation analysis
Enrichment for mutations with APOBEC3G/F signatures
was assessed using Hypermut 2.0 (www.hiv.lanl.gov)
[111]. For each intra-patient sequence set, the most recent
common ancestor (MRCA), a hypothetical viral sequence
representing the most recent viral variant from which a
subject’s viral quasispecies are descended was used as
the reference sequence. MRCAs were reconstructed in
DIVEIN using maximum likelihood methods [112]. Se-
quences that yielded a Fischer’s exact p-value of 0.05 or
lower were considered significantly hypermutated and ex-
cluded from analyses of sequence diversity.
Compartmentalization analysis
The Slatkin-Maddison test was used to detect population
structure amongst HIV-1 env sequences within individual
ML phylograms [62]. Implemented in the HyPhy software
package [63], this approach applies a parsimony criterion
to the evolution of each character on the maximum likeli-
hood gene phylogeny in question, and assesses the degreeof variation from the normal distribution of simulated
sequences over the tree to assess the degree of intercom-
partment segregation. The significance of group separ-
ation was determined using the permutation test (10,000
permutations). Shifts in population structure were also
calculated using a nonparameteric test for panmixia [60].
Derived from a geographic subdivision detection test
proposed by Hudson et al. [61], this test compares an
estimate of the degree of genetic differentiation in subpop-
ulations of single genome sequences (SGS) chosen for
comparison. The online version of this test was applied
from the site at http://wwwabi.snv.jussieu.fr/~achaz/
hudsontest.html. In the absence of genetic differentiation
between subpopulations, random reassignment of SGSs to
different groups would be expected to recapitulate a new,
imaginary population with population structures with the
same distribution as the experimentally observed subpop-
ulation. Ten thousand (10,000) re-labelings/permutations
were used to generate a p-value quantifying the statistical
significance of the compartmentalization estimate.Coreceptor usage phenotype determination
V3 loop nucleotide sequences were extracted from
multiply aligned full-length HIV-1 env for each partici-
pant using coordinates 7110-7216 on the HXB2 refer-
ence genome via the Gene cutter program on the HIV
Los Alamos website www.hiv.lanl.gov. Translated V3
loop sequences were scored using Geno2Pheno [66] and
the SINSI position-specific scoring matrix [PSSM] pre-
diction algorithm [67].N-glycosylation determination
The N-Glycosite webserver [79] on the Los Alamos HIV
database site (http://www.hiv.lanl.gov) was used to identify
potential N-linked glycosylation sites (PNLGS) across
HIV-1 env protein sequences.Compartmentalization signature pattern analysis
Signature pattern analysis was performed using the Viral
Epidemiology Signature Analysis (VESPA) software [80]
available on the Los Alamos HIV database site (http://
www.hiv.lanl.gov). For each individual, the amino acid
alignments of CSF-derived SGS (query) was compared to
the amino acid alignments of contemporaneous plasma-
derived SGS (background).Evaluation of the reliability of multiple sequence
alignments
The web-based GUIDANCE program (http://guidance.
tau.ac.il/overview.html) was used to construct a set of
multiple sequence alignments and evaluate their reliabil-
ity [81].
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Correlated mutations were detected using the CorMut
package (Bioconductor version: release 2.12) for the R
software environment for statistical computing and graph-
ics [82]. Individual codon-aligned multiple alignments
containing the reference plasma consensus sequence
followed by all paired CSF-derived SGS were used as in-
put. CorMut uses a mutual Information approach to de-
tect correlated mutations. For each pair of positions in
HXB2, a p-value was calculated by shuffling one of the
alignment columns 10,000 times, calculating new random
mutual information for each shuffled column and deter-
mining the fraction of random mutual informations that
are greater or equal to the true mutual information. A
mutual information (MI) score of 0.10 was chosen as a
cut-off and as an additional criteria, mutations were con-
sidered significantly correlated if the Benjamini–Hochberg
adjusted p-value for the correlation was less than 0.05
(corresponding to a 5% false discovery rate). The resulting
adjacency matrix representing correlations between amino
acids at investigated positions was constructed in CorMut.
Mapping of compartmentalization hot spot positions to
HIV-1 env trimer
To understand the spatial relation of the hot spot residues
and their potential functional implication, we mapped
these residues onto the recently published crystal struc-
ture of the SOSIP trimer (PDB ID 4NCO) [83]. To
illustrate the CD4 binding site on the trimer, a crystal
structure of gp120 core in complex with CD4 (PDB ID
1GC1) was superimposed with the SOSIP trimer and CD4
footprint was projected on the surface of the gp120 trimer.
The structural figures were rendered with Pymol software
package (http://www.pymol.org).
Statistical analyses
With the exception of correlated mutations, all statistical
analyses were performed using GraphPad Prism version
5.0d for Mac OS X, GraphPad Software, La Jolla California
USA, www.graphpad.com.
Availability of supporting data
All of the HIV-1 env sequences discussed in this manu-
script have been deposited in GenBank (accession num-
bers KM258899 - KM259615).
Additional files
Additional file 1: Figure S1. No significant correlation between
differences in Amino Acid Diversities and Viral Load Between
Compartments. Linear regression analysis comparing the ratio of each
subject’s plasma to CSF average pairwise distance (APD) to the log of the
ratio of the plasma to CSF HIV-1 RNA level (VL) is shown. The linear
regression score (r2) was derived in PRISM. P-values <0.05 are considered
significant.Additional file 2: Table S1. Bonferroni corrected p-value thresholds for
compartmentalization analyses. The number of variable sites as determined
in the MEGA 5.2 software in each subjects’ protein multiple-alignment
was used to calculate the corrected Bonferroni p-value threshold. Each
multiple-alignment was composed of the subjects CSF- and plasma-derived
single genomes. #CSF SGS and #Plasma SGS = number of SGS used in
analysis after exclusion of duplicate sequences within each compartment
and sequences with statistical evidence of hypermutation.
Additional file 3: Dataset S1. The Complete list of Amino acids for
each pair of sites exhibiting significant Mutual Information. Discrete
amino acid positions from patient alignments are identified by their
position in HXB2 gp160. Each site is identified by a nomenclature listing
the dominant amino acid in the plasma consensus for the patient,
followed by the HXB2 gp160 numbered position, concluding with the
dominant amino acid in the CSF-derived sequences that represents a
mutation from the dominant plasma consensus amino acid.
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